MwanzoATYR • NASDAQ
add
aTyr Pharma Inc
$Â 0.85
Baada ya Saa za Kazi:(2.12%)+0.018
$Â 0.87
Imefungwa: 13 Mac, 19:32:13 GMT -4 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$Â 0.87
Bei za siku
$Â 0.83 - $Â 0.90
Bei za mwaka
$Â 0.64 - $Â 7.29
Thamani ya kampuni katika soko
83.10M USD
Wastani wa hisa zilizouzwa
2.33M
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | — | — |
Matumizi ya uendeshaji wa biashara | 3.90M | 8.71% |
Mapato halisi | -13.96M | 6.71% |
Kiwango cha faida halisi | — | — |
Mapato kwa kila hisa | -0.14 | 22.22% |
EBITDA | -14.63M | 6.49% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 78.69M | 9.10% |
Jumla ya mali | 93.00M | -3.95% |
Jumla ya dhima | 25.72M | -4.75% |
Jumla ya hisa | 67.29M | — |
hisa zilizosalia | 98.05M | — |
Uwiano wa bei na thamani | 1.26 | — |
Faida inayotokana na mali | -37.05% | — |
Faida inayotokana mtaji | -43.08% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -13.96M | 6.71% |
Pesa kutokana na shughuli | -12.20M | 7.13% |
Pesa kutokana na uwekezaji | 16.44M | 370.22% |
Pesa kutokana na ufadhili | elfu -131.00 | -100.70% |
Mabadiliko halisi ya pesa taslimu | 4.12M | 1,188.89% |
Mtiririko huru wa pesa | -6.98M | 10.87% |
Kuhusu
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.
The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla. Wikipedia
Ilianzishwa
1 Jan 2005
Tovuti
Wafanyakazi
59
